Abstract A138: Evaluating medication adherence of oral endocrine therapy among breast cancer survivors in a large academic medical center
Rutugandha Paranjpe(Merck & Co., Inc., Rahway, NJ, USA (United States)), Meghana V. Trivedi(University of Houston), Kelvin Lu(Methodist Hospital), Susan Abughosh(University of Houston), Uzo Abajue(University of Houston), Hanna Zaghloul(Houston Methodist), Grace Hwang(University of Houston), Carine Opsomer(Methodist Hospital)
Cited by 1
Related Papers
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize
|Cancer Research|2018|221
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
|Breast Care|2013|200
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
|Proceedings of the National Academy of Sciences|2016|185
The changing role of ER in endocrine resistance
|The Breast|2015|133